One in two patients with metastatic melanoma alive after five years with combination immunotherapy #ESMO19

da Salute H24 — 28 settembre 2019 alle 15:49


One in two patients with metastatic melanoma is alivewith combination immunotherapy, according to late breaking results of the CheckMate 067 trial presented at the ESMO Congress 2019 in Barcelona, Spain. Continua »

AntonioCaperna

Scrivi un commento